Novel Glucagon/GLP-1 Agonist Meets Cardiovascular Safety Endpoint
(MedPage Today) -- Survodutide, an investigational glucagon receptor and GLP-1 receptor dual agonist, was safe for patients with obesity and either established cardiovascular disease (CVD), chronic kidney disease (CKD), or increased risk of CVD...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.